News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
708,275 Results
Type
Article (41987)
Company Profile (435)
Press Release (665853)
Section
Business (208593)
Career Advice (2019)
Deals (35990)
Drug Delivery (102)
Drug Development (83468)
Employer Resources (170)
FDA (16382)
Job Trends (15069)
News (352474)
Policy (33019)
Tag
Academia (2624)
Alliances (50839)
Alzheimer's disease (1360)
Approvals (16354)
Artificial intelligence (214)
Bankruptcy (367)
Best Places to Work (11841)
Biotechnology (329)
Breast cancer (231)
Cancer (1759)
Cardiovascular disease (138)
Career advice (1682)
CAR-T (127)
Cell therapy (374)
Clinical research (67029)
Collaboration (697)
Compensation (375)
COVID-19 (2623)
C-suite (167)
Data (1656)
Diabetes (216)
Diagnostics (6341)
Earnings (86672)
Employer resources (147)
Events (114377)
Executive appointments (578)
FDA (17301)
Funding (631)
Gene therapy (266)
GLP-1 (686)
Government (4444)
Healthcare (19097)
Infectious disease (2736)
Inflammatory bowel disease (127)
Interviews (310)
IPO (16740)
Job creations (3698)
Job search strategy (1432)
Layoffs (466)
Legal (7962)
Lung cancer (260)
Manufacturing (244)
Medical device (13410)
Medtech (13415)
Mergers & acquisitions (19617)
Metabolic disorders (580)
Neuroscience (1792)
NextGen: Class of 2025 (6750)
Non-profit (4545)
Northern California (2118)
Obesity (325)
Opinion (212)
Patents (164)
People (58203)
Phase I (21054)
Phase II (29593)
Phase III (21857)
Pipeline (728)
Postmarket research (2601)
Preclinical (8967)
Radiopharmaceuticals (257)
Rare diseases (343)
Real estate (6005)
Regulatory (22377)
Research institute (2406)
Resumes & cover letters (351)
Southern California (1826)
Startups (3753)
United States (18958)
Vaccines (630)
Weight loss (227)
Date
Today (12)
Last 7 days (609)
Last 30 days (2581)
Last 365 days (35457)
2025 (4559)
2024 (36299)
2023 (41015)
2022 (52276)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (734)
Arizona (219)
Asia (38917)
Australia (6478)
California (4885)
Canada (1725)
China (403)
Colorado (221)
Connecticut (242)
Europe (84925)
Florida (692)
Georgia (165)
Illinois (471)
Indiana (262)
Maryland (759)
Massachusetts (3757)
Michigan (200)
Minnesota (340)
New Jersey (1374)
New York (1379)
North Carolina (897)
Northern California (2118)
Ohio (175)
Pennsylvania (1112)
South America (1107)
Southern California (1826)
Texas (717)
Utah (145)
Washington State (485)
708,275 Results for "novelmed therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
NovelMed Receives FDA IND Approval for NM8074 (Ruxoprubart), the First Anti-Bb Alternative Pathway Blocker for Treating Primary Immunoglobulin A Nephropathy (IgAN): A Renal Disorder
December 3, 2024
·
5 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Drug Development
NovelMed Commences Phase II Trial for Anti-Bb Antibody (NM8074) in Treatment-Naïve PNH Patients: A Glimpse into the PNH Study Progress
NovelMed Therapeutics is excited to announce the commencement of its Phase II clinical trial targeting treatment-naïve Paroxysmal Nocturnal Hemoglobinuria (PNH) patients with its groundbreaking anti-Bb antibody, NM8074.
October 30, 2023
·
5 min read
Press Releases
Windtree Therapeutics, Inc. Announces Reverse Stock Split
February 19, 2025
·
7 min read
Press Releases
Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.
January 23, 2025
·
5 min read
Press Releases
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
February 4, 2025
·
7 min read
Drug Development
NovelMed Phase I Clinical Trial Shows Inhibition of the Alternative Pathway and Preservation of the Classical Pathway – A Long-Acting Anti-Properdin Monoclonal Antibody NM3086 for PNH Patients
NovelMed Therapeutics, Inc. announced today topline results from First-in-Human Phase I clinical trial of its complement blocker monoclonal anti-Properdin antibody, known as NM3086.
June 5, 2023
·
6 min read
Press Releases
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Engage BTIG as Financial Advisor
February 3, 2025
·
7 min read
Press Releases
Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck
February 12, 2025
·
4 min read
Press Releases
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025
February 7, 2025
·
4 min read
1 of 70,828
Next
